← Back to Clinical Trials
Recruiting NCT07377513

NCT07377513 Follow-up Compliance for Corneal Ulcer Patients With SMS Reminder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07377513
Status Recruiting
Phase
Sponsor Seva Canada Society
Condition Corneal Ulcer
Study Type INTERVENTIONAL
Enrollment 310 participants
Start Date 2026-02-23
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
SMS reminder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 310 participants in total. It began in 2026-02-23 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Corneal ulcer is defined as the loss of corneal epithelium with underlying stromal infiltration and suppuration, accompanied by signs of inflammation, with or without hypopyon1. The condition may be caused by bacterial, fungal, viral or parasitic pathogens and carries a significant risk of corneal perforation and subsequent visual impairment2. These risks highlight the importance of timely treatment plans and consistent referral networks3. A lot of patients choose to self-medicate and postpone seeking professional assistance due either their lack of awareness or forgetfulness, which results in inadequate follow-up compliance4,5. Scheduling appointments regularly is still a significant barrier to successful treatment and visual recovery. SMS reminders have shown encouraging real-world success in improving follow-up attendance with in ophthalmology. Mobile health tools, such as the peek Community Eye Health system, have proven increased follow-up rates and improved access to eye care services in low-resource setting through automated appointment reminders and patient monitoring6. The aim of this operational research study to evaluated the feasibility, scalability, and effectiveness of SMS reminders in improving follow-up compliance among patients with corneal ulcer at the Lumbini Eye Institute and Research Center (LEIRC), Western Nepal. The findings are expected to inform the integration of cost-effective digital health strategies to strengthen patient adherence, optimize clinical outcomes, and support eye health programs in resource limited environments.

Eligibility Criteria

Inclusion Criteria: * Newly diagnosed patients (18 to 70 years) of corneal ulcer in one or both eye, who are medically managed, visiting the OPD at LEIRC and have access to a mobile phone. Exclusion Criteria: * Less than 18 years or more than 70 years Patients who do not have a access to a mobile phone.

Contact & Investigator

Central Contact

Saraswati Khadka Thapa

✉ research@lei.org.np, sarukhadkathapa555@gmail.com

📞 +9779847110218 / 071-573827

Frequently Asked Questions

Who can join the NCT07377513 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Corneal Ulcer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07377513 currently recruiting?

Yes, NCT07377513 is actively recruiting participants. Contact the research team at research@lei.org.np, sarukhadkathapa555@gmail.com for enrollment information.

Where is the NCT07377513 trial being conducted?

This trial is being conducted at Siddharthanagar, Nepal.

Who is sponsoring the NCT07377513 clinical trial?

NCT07377513 is sponsored by Seva Canada Society. The trial plans to enroll 310 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology